BGG492

DRUG7 trials

Sponsors

Novartis Pharmaceuticals, Novartis

Conditions

Adrenocortical AdenomaEndometrial Stromal SarcomasMigraineMuscle Spasticity Due to Multiple SclerosisPartial Onset SeizuresPatients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the ScreeningPhotosensitive Epilepsy

Phase 2

Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

CompletedNCT00784212

Novartis PharmaceuticalsPhotosensitive Epilepsy

Start: 2008-10-31End: 2010-09-30Updated: 2016-09-23

Efficacy and Safety of BGG492 in the Treatment of Migraine

CompletedNCT00892203

NovartisMigraine

Start: 2009-04-30End: 2010-08-31Updated: 2020-12-17

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

WithdrawnNCT01167335

NovartisPartial Onset Seizures

Start: 2010-08-31Updated: 2012-05-01

Phase II BGG492 Capsule Extension for Partial Epilepsy

CompletedNCT01338805

Novartis PharmaceuticalsPartial Onset Seizures

Start: 2011-06-30End: 2012-07-31Updated: 2021-03-05

A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention

WithdrawnNCT01617941

Novartis PharmaceuticalsPatients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening

Start: 2016-05-31End: 2016-11-30Updated: 2017-04-20

Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis

WithdrawnNCT01649050

Novartis PharmaceuticalsMuscle Spasticity Due to Multiple Sclerosis

Start: 2016-10-31End: 2018-03-31Updated: 2017-04-20

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

CompletedNCT02150213

Novartis PharmaceuticalsAdrenocortical Adenoma, Endometrial Stromal Sarcomas

Start: 2014-08-31End: 2015-09-30Updated: 2016-12-05